Hosted on MSN3mon
Lilly Alzheimer's drug not to be covered by U.K.'s NHS: reportU.K. regulators will reportedly recommend that the National Health Service not cover Eli Lilly’s (NYSE:LLY) donanemab for the treatment of early Alzheimer’s disease because it’s too expensive.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback